Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Neurosurg. 2021 Jun 4;136(1):1–8. doi: 10.3171/2020.10.JNS203366

Figure 2:

Figure 2:

Survival of patients with GBM who underwent GTR of CE tumor according to MGMT promoter methylation status. The mean survival of patients with methylated MGMT promoter was 21.4 months compared with 18.6 months for patients with unmethylated MGMT promoter (p = 0.043).